Biotechnology
Tianlong Announces Global Release of GeneFlex Nucleic Acid Extractor and Gentier mini+ Real-time PCR System
Featuring flexibility and portability, the two products are ideal for small
laboratories or on-site testing needs.
XI'AN, China, March 31, 2023 /PRNewswire/ -- Tianlong
2023-03-31 20:04
3476
Qiming Venture Partners Welcomes Apollomics' Successful IPO on Nasdaq
SHANGHAI, March 31, 2023 /PRNewswire/ -- On March 30, 2023, Apollomics Inc. ("Apollomics"), an innovative biopharmaceutical company and portfolio company of Qiming Venture Partners, listed on Nasdaq through a SPAC merger with Maxpro Capital Acquisition Corp. The combined company is now traded und...
2023-03-31 20:01
4504
Hugel Appointed Suk-yong Cha as Executive Chairman and Chairman of the Board Accelerating Transformation into a Global Top-tier Company
- Appointed as Executive Chairman and Chairman of the Board at the General Meeting of Shareholders and Board of Directors meeting on the 30th - Chairman Cha will lead the growth of Hugel based on his aesthetics know-how and experience in pioneering global markets SEOUL, South Korea, March 31, 20...
2023-03-31 20:00
2006
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022
* Strategic reprioritization of the Company's pipeline to focus on key clinical assets and overall streamlining of corporate structure and workforce, resulting in a significant reduction in the cash burn rate and in significant pipeline achievements by focus * Thirteen key clinical milestones...
2023-03-31 18:30
4340
Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China
SHANGHAI, March 31, 2023 /PRNewswire/ -- Ablaze Pharmaceuticals, a biotech company that is focused on developing Targeted Radiotherapy (TRT) to benefit cancer patients inChina, today announced the development plans of a first-in-class novel peptide drug candidate against GPC3. The proprietary GPC...
2023-03-31 10:00
2815
Genscript Biotech Reports 2022 Annual Results*
Non-Cell Therapy Achieved 31.4% Adjusted Net Profit Growth Cell Therapy Business Revenue Surged By 70% * Revenue of the Group for the year ended December 31, 2022 was approximately US$625.7 million, representing an increase of 27.7% as compared with approximatelyUS$490.1 million for the year e...
2023-03-31 08:40
2920
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2022
SHANGHAI, March 31, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing, manufacturing and commercializing transformative pharmaceutical products and vaccines, today announced its financial results for the full year...
2023-03-31 07:30
3973
NADclinic Group, BioStarks and Do Not Age Announce Exclusive Partnership to Revolutionise Personalised Longevity
LONDON, March 31, 2023 /PRNewswire/ -- NADclinic Group, BioStarks and Do Not Age have joined forces in an exclusive partnership to provide their audience with innovative solutions, combining cutting edge diagnostics, therapeutics and best in class longevity focused supplements and nutraceuticals....
2023-03-31 03:03
2583
Kintor Pharma Announces 2022 Annual Results and Recent Business Progress
SUZHOU, China, March 30, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced business highlights and financial results for the year ended31 Decembe...
2023-03-31 00:33
3261
Viva Biotech Announced 2022 Annual Results:
Revenue and Gross Profit with Steady Growth Competitive Advantages of One-stop Platform Continuously Demonstrating Financial highlights of the year ended December 31, 2022: * Revenue amounted to RMB2,379.6 million, representing a year-on-year (YoY) increase of 13.1% * Gross profit amounted to...
2023-03-31 00:25
3670
DISCOVERY LIFE SCIENCES INSTALLS WORLD'S LARGEST COMMERCIAL FLEET OF NOVASEQ X PLUS SYSTEMS TO ACCELERATE GENOMIC RESEARCH WITH UNPRECEDENTED SPEED AND COST EFFICIENCY
HUNTSVILLE, Ala., March 30, 2023 /PRNewswire/ -- Discovery Life Sciences™ (Discovery), the Biospecimen and Biomarker Specialists™, has announced that Discovery Genomics is the first commercial service laboratory in the world to receive two of the new NovaSeq™ X Plus Sequencing Systems from Illumi...
2023-03-30 21:05
2202
Actinogen presents positive Phase 2a Xanamem data in at ADPD™ Alzheimer's and Parkinson's diseases conference
A longitudinal dataset indicating the utility of plasma pTau for patient selection in clinical trials of patients with mild Alzheimer's Disease (AD) and the likely therapeutic benefit of oral Xanamem in this population SYDNEY, March 30, 2023 /PRNewswire/ -- Actinogen Medical ASX: ACW ("ACW" or "...
2023-03-30 21:00
1804
ACROBiosystems' new strategic focus - streamlining the transition from preclinical development to commercialization
BASEL, Switzerland, March 30, 2023 /PRNewswire/ -- ACROBiosystems has begun to narrow its focus into helping accelerate the process between preclinical, clinical and commercialization. With over 10 years development, ACROBiosystems continues to surprise and bring new solutions to the pharmaceutic...
2023-03-30 20:51
1955
Turn Biotechnologies Introduces its Dermatology Platform to the European Aesthetic Community at AMWC
MOUNTAIN VIEW, Calif., March 30, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, announced that it will for the first time share new data for its revolutionary dermatology platform with the interna...
2023-03-30 20:00
3283
ACROBiosystems' new strategic focus - streamlining the transition from preclinical development to commercialization
NEWARK, Del., March 30, 2023 /PRNewswire/ -- With more than 10 years of experience in protein development, ACROBiosystems has continuously demonstrated its strength in developing products and services throughout the entire drug development process. As such, ACROBiosystems has begun to narrow its ...
2023-03-30 18:54
1876
DxVx Co., Ltd.'s affiliated company, Oxford Vacmedix (OVM) successfully completed Phase 1a in clinical trial of novel cancer vaccine OVM-200
SEOUL, South Korea, March 30, 2023 /PRNewswire/ -- DXVX announces that its affiliated company Oxford Vacmedix (OVM) has completed Phase 1a trial of cancer vaccine and plans to proceed Phase1b trial of OVM-200. DxVx Co., Ltd. is the Korean Stock market (KOSDAQ) listed company and is the largest s...
2023-03-30 17:39
1918
Zylox-Tonbridge Announces Financial Results for 2022: Revenue Increases by 87.8% YOY to RMB 334 million and Gross Profit Reaches RMB 253 million
HANGZHOU, China, March 30, 2023 /PRNewswire/ -- On March 29, 2023, Zylox-Tonbridge Medical Technology Co., Ltd. (2190. HK, hereinafter referred to as the "Company") released its annual financial results for 2022. During the reporting period, the Company's operating revenue increased by 87.8% YOY ...
2023-03-30 15:49
2067
Great Place To Work unveils Best Workplaces in the Inaugural Singapore Healthcare and Biopharma List 2023
Employees express trust in leaders' competence and integrity and value fairness and impartiality as part of the workplace culture SINGAPORE, March 30, 2023 /PRNewswire/ -- Great Place To Work®, the global authority on workplace culture announced the 10 companies who are Best WorkplacesTM in its ...
2023-03-30 12:00
2497
ImmVira's oncolytic product MVR-C5252 targeting malignant glioma obtained NMPA's approval for Clinical Trial in China
SHENZHEN, China, March 29, 2023 /PRNewswire/ -- ImmVira announced that its oncolytic virus product MVR-C5252 targeting malignant glioma obtained the approval from National Medical Products Administration ("NMPA") for Phase I clinical trial inChina on March 29, 2023. Previously, MVR-C5252 also obt...
2023-03-30 08:00
1742
JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 406 Patients
SHANGHAI, March 30, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that as ofMarch 29, 2023, the company has conducted 13 clinical studies cover...
2023-03-30 08:00
2751
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9271
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7748